September 10th 2016: Join Us for Wheel to Survive Lubbock
What is Wheel to Survive?
Wheel to Survive is an uplifting, inspirational indoor cycling fundraiser to benefit programs for women currently battling ovarian cancer and to provide research dollars for a CURE. Cyclists of all skill levels are welcome to participate!
Wheel to Survive Lubbock 2016 will be held on Saturday, September 10, 2016 from 10:00 a.m. – 12:00 p.m. at the Texas Tech Recreation Center, 2500 Broadway, Lubbock, Texas 79409.
How to Participate:
Register to ride by paying the $40 registration fee and setting up your fundraising page. Your registration fee includes a Wheel to Survive Lubbock event t-shirt, FREE training rides leading up to the event and a goodie bag you will receive the day of the ride.
Simply share your fundraising profile with family, friends and coworkers, and ask them to consider making a tax-deductible donation to your ride or (better yet) register to ride and join you at Wheel to Survive Lubbock!
Fundraising requirement:
$125 minimum each for rider
Ovarian Cancer Survivors
Registration fees are waived for ovarian cancer survivors.
Student Riders
The registration fee for students is $25 with a $100 minimum fundraising commitment for each rider.
We hope you join us! Register today to ride!
Why You Should Ride:
Women with ovarian cancer need your help. Ovarian cancer is the most lethal gynecological cancer affecting 1 in 70 women. Today more than 70% of ovarian cancer patients will die of their disease, compared to less than 20% of breast cancer patients. When ovarian cancer is detected and treated early, the five year survival rate is greater than 92%. Sadly, symptoms are vague and subtle, so most patients are diagnosed at later stages. Less than 50% will survive more than 5 years after their diagnosis.
IT IS TIME TO CHANGE THESE STATISTICS FOR OUR MOTHERS, DAUGHTERS, SISTERS AND GIRLFRIENDS AND BE THE DIFFERENCE IN THE FIGHT AGAINST OVARIAN CANCER TODAY!
We need your help to raise money and awareness. Together we can be the difference in the fight against ovarian cancer.